Ajovy (fremanezumab) wins US approval in migraine prevention
Ajovy (fremanezumab) has become the second anti-CGRP agent to gain approval for migraine prophylaxis in adults in the USA. It is the first and only anti-CGRP treatment with both monthly (220 mg) and quarterly (675 mg) dosing options.
“About 40% of people living with migraine may be appropriate candidates for preventive treatment, yet the majority of them are untreated. I am pleased to have another treatment option that may allow my patients to experience fewer monthly migraine days,” said Professor Stephen Silberstein, Director, Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, USA, and lead investigator of the Phase III clinical trial programme for fremanezumab.
Read the full report here »
|Becoming a member is easy|
Members have free open access simply by registering online.